Scott J. Rodig, Ph.D., M.D.
This page shows the publications co-authored by Scott Rodig and A. Look.
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. Oncogene. 2021 Jul 30.
Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. Dis Model Mech. 2019 05 07; 12(5).
Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Oncogene. 2017 02 23; 36(8):1058-1068.
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016 Jan; 30(1):190-9.
A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. Mol Cell Biol. 2015 Mar; 35(5):789-804.
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol. 2015 Jan; 168(2):230-8.
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013 Jul 16; 2:e00825.
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 2013 Jan; 27(1):66-74.
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012 Jul; 18(7):1118-22.
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012 Mar 20; 21(3):362-73.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.